WO2001039763A3 - Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors - Google Patents
Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors Download PDFInfo
- Publication number
- WO2001039763A3 WO2001039763A3 PCT/US2000/033104 US0033104W WO0139763A3 WO 2001039763 A3 WO2001039763 A3 WO 2001039763A3 US 0033104 W US0033104 W US 0033104W WO 0139763 A3 WO0139763 A3 WO 0139763A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methylol
- tumors
- medicament
- manufacture
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00983966A EP1248625A2 (en) | 1999-12-06 | 2000-12-06 | Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
CA002393252A CA2393252A1 (en) | 1999-12-06 | 2000-12-06 | Use of methylol-containing compounds to treat tumors |
JP2001541496A JP2003515558A (en) | 1999-12-06 | 2000-12-06 | Use of a methylol-containing compound to treat a tumor |
AU20650/01A AU784538B2 (en) | 1999-12-06 | 2000-12-06 | Use of methylol-containing compounds to treat tumors |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16912299P | 1999-12-06 | 1999-12-06 | |
US16912899P | 1999-12-06 | 1999-12-06 | |
US16912799P | 1999-12-06 | 1999-12-06 | |
US60/169,128 | 1999-12-06 | ||
US60/169,127 | 1999-12-06 | ||
US60/169,122 | 1999-12-06 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10012266.2A Previously-Filed-Application EP2332542B1 (en) | 1999-12-06 | 2000-12-06 | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001039763A2 WO2001039763A2 (en) | 2001-06-07 |
WO2001039763A3 true WO2001039763A3 (en) | 2002-07-11 |
Family
ID=27389609
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/033104 WO2001039763A2 (en) | 1999-12-06 | 2000-12-06 | Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
PCT/US2000/033103 WO2001039762A2 (en) | 1999-12-06 | 2000-12-06 | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/033103 WO2001039762A2 (en) | 1999-12-06 | 2000-12-06 | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
Country Status (9)
Country | Link |
---|---|
US (6) | US6521616B2 (en) |
EP (3) | EP1246617B1 (en) |
JP (5) | JP5027369B2 (en) |
AT (1) | ATE339207T1 (en) |
AU (2) | AU784539B2 (en) |
CA (3) | CA2393159C (en) |
DE (1) | DE60030770T2 (en) |
ES (2) | ES2438535T3 (en) |
WO (2) | WO2001039763A2 (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060199811A1 (en) * | 1997-07-31 | 2006-09-07 | Pfirrmann Rolf W | Method of treatment for preventing or reducing tumor growth in the liver of patient |
US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
US6479481B1 (en) | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
US20030027818A1 (en) | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
US20070275955A1 (en) * | 1997-07-31 | 2007-11-29 | Ed. Geistlich Soehne Ag | Method of treating tumors |
US8304390B2 (en) * | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
US8030301B2 (en) | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
US20030225067A1 (en) * | 1999-06-04 | 2003-12-04 | Ruediger Stendel | Microdialysis methods and applications for treatment and/or prophylaxis of tumors and/or infections in the central nervous system (CNS) and/or in other parenchymal organs |
US7892530B2 (en) | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
US7345039B2 (en) * | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
EP1797884B1 (en) * | 1999-12-06 | 2013-09-11 | Geistlich Pharma AG | Taurolidine or taurultam for use in the treatment of tumors of the prostate, colon, lung and for the treatment of recurrent glioblastoma multiforme |
CN100519525C (en) * | 1999-12-06 | 2009-07-29 | 葛兰素集团有限公司 | Aromatic sulfones and their medical use |
US6521616B2 (en) * | 1999-12-06 | 2003-02-18 | Rhode Island Hospital, A Lifespan Partner | Methods of treating tumors with taurolidine |
US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
AU779362B2 (en) | 2000-10-27 | 2005-01-20 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
US20020081339A1 (en) * | 2000-12-22 | 2002-06-27 | Philippe Menei | Treatment of inoperable tumors by stereotactic injection of microspheres |
GB0104383D0 (en) * | 2001-02-22 | 2001-04-11 | Psimedica Ltd | Cancer Treatment |
WO2002074294A1 (en) * | 2001-03-15 | 2002-09-26 | Rhode Island Hospital, A Lifespan Partner | Taurine compounds |
US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
US20080171738A1 (en) * | 2001-04-03 | 2008-07-17 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of Breast Cancer |
US6753328B2 (en) * | 2001-10-01 | 2004-06-22 | Rhode Island Hospital | Methods of inhibiting metastases |
CA2412012C (en) | 2001-11-20 | 2011-08-02 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage |
ATE333298T1 (en) * | 2002-03-21 | 2006-08-15 | Geistlich Soehne Ag | DEVICE FOR TREATING A TUMOR IN THE CENTRAL NERVOUS SYSTEM |
DE60313344T2 (en) * | 2002-09-24 | 2008-01-03 | Novartis Ag | USE OF 4-PYRIDYLMETHYL-PHTHALAZINE DERIVATIVES FOR THE PRODUCTION OF A MEDICAMENT FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES |
US7167750B2 (en) * | 2003-02-03 | 2007-01-23 | Enteromedics, Inc. | Obesity treatment with electrically induced vagal down regulation |
JP5346148B2 (en) * | 2003-03-28 | 2013-11-20 | エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー | Antineoplastic compositions and methods of treatment |
US20050008684A1 (en) * | 2003-07-10 | 2005-01-13 | Claus Herdeis | Method of treatment for acne, rosacea and ulcers with taurolidine and/or taurultam in a pharmaceutical composition |
JP5043294B2 (en) | 2003-09-29 | 2012-10-10 | エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー | How to treat mesothelioma |
JP2007537200A (en) * | 2004-05-14 | 2007-12-20 | ハンス−ディートリヒ・ポラシェグ | Taurolidine formulation and administration: therapeutic treatment and antibacterial protection against bacterial microfilm formation |
AU2005265027A1 (en) * | 2004-06-18 | 2006-01-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells |
PL1904093T3 (en) * | 2005-07-19 | 2018-12-31 | Stemgen S.P.A. | Inhibition of the tumorigenic potential of tumor stem cells by bmp-4 |
WO2007020509A1 (en) * | 2005-08-15 | 2007-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth |
ATE532519T1 (en) * | 2006-01-06 | 2011-11-15 | Geistlich Soehne Ag | RADIATED COMPOSITIONS AND TREATMENT OF CANCER USING RADIATION IN COMBINATION WITH TAUROLIDINE AND/OR TAURULTAM |
CA2661409A1 (en) * | 2006-09-05 | 2008-03-13 | Myron Spector | Method of improving renal function |
CN101528195B (en) * | 2006-09-07 | 2012-03-28 | 埃德盖斯特利希索恩化学工业股份公司 | Use of hydroxymethyl transferring agent in preparing medicine for treating bone cancer |
EP2240175B1 (en) * | 2008-02-11 | 2013-01-02 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Compounds with mdr1-inverse activity |
DE102010010360A1 (en) * | 2010-03-05 | 2011-09-08 | Gamptec Gmbh | Taurolidine formulations and process for its preparation |
ES2614878T3 (en) * | 2010-06-01 | 2017-06-02 | Geistlich Pharma Ag | Methods and compositions for oral pharmaceutical therapy |
US8852617B2 (en) | 2010-09-27 | 2014-10-07 | Geistlich Pharma Ag | Antimicrobial dental care preparation |
PL2861573T3 (en) | 2012-06-18 | 2018-02-28 | Geistlich Pharma Ag | Oxathiazine derivatives as antibacterial and anticancer agents. |
TN2016000179A1 (en) * | 2013-12-06 | 2017-10-06 | Novartis Ag | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. |
CA3000868A1 (en) * | 2015-10-07 | 2017-04-13 | Cormedix Inc. | Skin-penetrating formulation of taurolidine |
US20170196875A1 (en) * | 2016-01-11 | 2017-07-13 | Cormedix Inc. | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers |
US11541061B2 (en) | 2016-01-11 | 2023-01-03 | Cormedix Inc. | Neuroblastoma treatment with taurolidine hydrolysis products |
US20190381058A1 (en) * | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Methods and compositions for treating neuroblastoma in a juvenile mammalian body |
WO2018126133A1 (en) * | 2016-12-29 | 2018-07-05 | Cormedix Inc. | Skin-penetrating formulation of taurolidine |
CN109929804B (en) * | 2017-12-15 | 2020-10-16 | 天津医科大学肿瘤医院 | Human ovarian cancer cell line and preparation method and application thereof |
CA3111057A1 (en) * | 2018-08-28 | 2020-02-05 | Cormedix Inc. | Neuroblastoma treatment with taurolidine hydrolysis products |
EP3843745A4 (en) * | 2018-08-28 | 2022-06-15 | CorMedix Inc. | Methods and compositions for treating neuroblastoma in a juvenile mammalian body |
CN113226325A (en) * | 2018-08-31 | 2021-08-06 | 科医公司 | Treatment of MYC expressing tumors in mammals with taurolidine |
WO2020234833A1 (en) | 2019-05-22 | 2020-11-26 | Geistlich Pharma Ag | Method for treating, preventing, inhibiting or reducing cytokine release |
US20220323452A1 (en) | 2019-05-22 | 2022-10-13 | Geistlich Pharma Ag | Methods and compositions for inhibiting gapdh |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990006138A1 (en) * | 1988-11-30 | 1990-06-14 | Ed Geistlich Söhne Ag Für Chemische Industrie | Implant for use in bone surgery |
WO1992000743A1 (en) * | 1990-07-09 | 1992-01-23 | Ed Geistlich Söhne Ag Für Chemische Industrie | Use of taurolidine and/or taurultam for the treatment of tumours |
WO1994003174A1 (en) * | 1992-07-30 | 1994-02-17 | Ed Geistlich Söhne Ag Für Chemische Industrie | Treatment of dentoalveolar infections with taurolidine and/or taurultam |
WO1998052572A1 (en) * | 1997-05-22 | 1998-11-26 | Oklahoma Medical Research Foundation | Use of taurolidine for treatment of leukemias |
EP1066830A2 (en) * | 1999-06-04 | 2001-01-10 | Ed. Geistlich Söhne Ag Für Chemische Industrie | Uses and compositions for treating primary and secondary tumors of the central nervous system (cns) |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1124285A (en) | 1964-10-06 | 1968-08-21 | Geistlich Soehne Ag | Novel perhydro-1,2,4-thiadiazine dioxides-(1,1), their preparation and compositionscontaining them |
GB1408010A (en) | 1972-11-20 | 1975-10-01 | Geistlich Soehne Ag | Sulphamoylphenyl-imidazolidinones |
GB1557163A (en) * | 1975-06-24 | 1979-12-05 | Geistlich Soehne Ag | Dental care preparations |
US4107305A (en) * | 1975-08-04 | 1978-08-15 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Treatment of endotoxaemia |
GB1588110A (en) | 1978-05-31 | 1981-04-15 | Geistlich Soehne Ag | Pharmaceutical compositions for the treatment of scars |
US4192302A (en) * | 1978-09-12 | 1980-03-11 | Boddie Arthur W | Hepatic isolation and perfusion circuit assembly |
JPS5598170A (en) * | 1979-01-18 | 1980-07-25 | Mitsui Toatsu Chem Inc | 5-fluorouracil derivative and its preparation |
US4337251A (en) * | 1979-05-09 | 1982-06-29 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Method of avoiding and removing adhesions |
CA1190855A (en) * | 1980-09-03 | 1985-07-23 | Rolf W. Pfirrmann | Treatment of osteitis |
GB8328074D0 (en) | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compositions |
GB8328111D0 (en) | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compounds |
GB8328073D0 (en) * | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compounds |
US5206352A (en) * | 1986-03-28 | 1993-04-27 | Board Of Trustees Of The University Of Illinois | Compositions for clones containing DNA sequences associated with multidrug resistance in human cells |
GB8617482D0 (en) | 1986-07-17 | 1986-08-28 | Geistlich Soehne Ag | Pharmaceutical composition |
US5210083A (en) * | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
US5573771A (en) * | 1988-08-19 | 1996-11-12 | Osteomedical Limited | Medicinal bone mineral products |
US5819748A (en) | 1988-11-30 | 1998-10-13 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Implant for use in bone surgery |
US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
GB9005856D0 (en) * | 1990-03-15 | 1990-05-09 | Geistlich Soehne Ag | Compositions |
EP0521225B1 (en) * | 1991-07-04 | 1994-10-12 | Hawe Neos Dental Dr. H. v. Weissenfluh SA | Pharmaceutical preparation for treatment of periodontitis, containing clavulanic acid |
US5635532A (en) * | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
FR2728790B1 (en) * | 1994-12-29 | 1997-01-24 | Cird Galderma | COMPOSITION MODULATING APOPTOSIS COMPRISING METHONIAL OR ANY FACTOR INFLUENCING THE INTRACELLULAR METHONIAL RATE |
US5954687A (en) | 1995-04-28 | 1999-09-21 | Medtronic, Inc. | Burr hole ring with catheter for use as an injection port |
US5976822A (en) | 1995-05-18 | 1999-11-02 | Coulter International Corp. | Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis |
GB9600426D0 (en) | 1996-01-10 | 1996-03-13 | Ed Geistlich Sohne A G | Compositions |
DE19606897C2 (en) * | 1996-02-13 | 2002-08-29 | Geistlich Soehne Ag | Means for preventing the spread of tumor cells and the development of trocar metastases in open and laparoscopic surgery of malignant tumors |
GB9716219D0 (en) | 1997-07-31 | 1997-10-08 | Geistlich Soehne Ag | Prevention of metastases |
US6011030A (en) * | 1997-09-22 | 2000-01-04 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Method of treating symptoms of microbial infection or sepsis |
US5972933A (en) * | 1998-01-08 | 1999-10-26 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Method of treating microbial infections |
US6117868A (en) * | 1998-09-16 | 2000-09-12 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Treatment of gastrointestinal ulcers or gastritis caused by microbial infection |
US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
US6521616B2 (en) * | 1999-12-06 | 2003-02-18 | Rhode Island Hospital, A Lifespan Partner | Methods of treating tumors with taurolidine |
US6448030B1 (en) * | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
US6670330B1 (en) * | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
-
2000
- 2000-12-06 US US09/730,666 patent/US6521616B2/en not_active Expired - Lifetime
- 2000-12-06 JP JP2001541495A patent/JP5027369B2/en not_active Expired - Fee Related
- 2000-12-06 US US09/730,923 patent/US6429224B1/en not_active Expired - Lifetime
- 2000-12-06 US US09/731,214 patent/US6964959B2/en not_active Expired - Lifetime
- 2000-12-06 CA CA2393159A patent/CA2393159C/en not_active Expired - Lifetime
- 2000-12-06 ES ES06019082.4T patent/ES2438535T3/en not_active Expired - Lifetime
- 2000-12-06 WO PCT/US2000/033104 patent/WO2001039763A2/en active Application Filing
- 2000-12-06 AU AU20649/01A patent/AU784539B2/en not_active Ceased
- 2000-12-06 ES ES10012266.2T patent/ES2531547T3/en not_active Expired - Lifetime
- 2000-12-06 EP EP00983965A patent/EP1246617B1/en not_active Expired - Lifetime
- 2000-12-06 EP EP10012266.2A patent/EP2332542B1/en not_active Expired - Lifetime
- 2000-12-06 CA CA002393252A patent/CA2393252A1/en not_active Abandoned
- 2000-12-06 JP JP2001541496A patent/JP2003515558A/en not_active Withdrawn
- 2000-12-06 DE DE60030770T patent/DE60030770T2/en not_active Expired - Lifetime
- 2000-12-06 CA CA2696185A patent/CA2696185C/en not_active Expired - Lifetime
- 2000-12-06 EP EP00983966A patent/EP1248625A2/en not_active Withdrawn
- 2000-12-06 AT AT00983965T patent/ATE339207T1/en active
- 2000-12-06 WO PCT/US2000/033103 patent/WO2001039762A2/en active IP Right Grant
- 2000-12-06 AU AU20650/01A patent/AU784538B2/en not_active Ceased
-
2002
- 2002-08-05 US US10/212,401 patent/US6703413B2/en not_active Expired - Lifetime
- 2002-11-21 US US10/301,263 patent/US6995164B2/en not_active Expired - Lifetime
-
2006
- 2006-02-07 US US11/350,313 patent/US20060135513A1/en not_active Abandoned
-
2012
- 2012-02-24 JP JP2012038079A patent/JP5829948B2/en not_active Expired - Fee Related
-
2014
- 2014-07-29 JP JP2014153442A patent/JP6234340B2/en not_active Expired - Fee Related
-
2016
- 2016-07-29 JP JP2016149539A patent/JP2016188244A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990006138A1 (en) * | 1988-11-30 | 1990-06-14 | Ed Geistlich Söhne Ag Für Chemische Industrie | Implant for use in bone surgery |
WO1992000743A1 (en) * | 1990-07-09 | 1992-01-23 | Ed Geistlich Söhne Ag Für Chemische Industrie | Use of taurolidine and/or taurultam for the treatment of tumours |
WO1994003174A1 (en) * | 1992-07-30 | 1994-02-17 | Ed Geistlich Söhne Ag Für Chemische Industrie | Treatment of dentoalveolar infections with taurolidine and/or taurultam |
WO1998052572A1 (en) * | 1997-05-22 | 1998-11-26 | Oklahoma Medical Research Foundation | Use of taurolidine for treatment of leukemias |
EP1066830A2 (en) * | 1999-06-04 | 2001-01-10 | Ed. Geistlich Söhne Ag Für Chemische Industrie | Uses and compositions for treating primary and secondary tumors of the central nervous system (cns) |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001039763A3 (en) | Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors | |
AU2005202257C1 (en) | Azacyclic compounds for use in the treatment of serotonin related diseases | |
BR0211228A (en) | Compound, pharmaceutical composition and its uses | |
ATE370138T1 (en) | NEW IMIDAZOPYRIDINES AND THEIR USE | |
ATE319447T1 (en) | PHARMACEUTICAL PREPARATIONS CONTAINING CLAVULANIC ACID OR DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
HK1104968A1 (en) | Use of immunomodulatory compounds in the manufacture of a medicament for the treatment and management of cancers and other diseases, and compositions thereof | |
NO20022014L (en) | A solid oral controlled release dosage form containing hydrocodone | |
DK1223980T3 (en) | Use of CSF-1 Inhibitors | |
NZ545506A (en) | Therapeutic agents useful for treating pain | |
WO2002036135A3 (en) | Compositions for antitumour treatment containing ecteinascidin 743 | |
NO20050569L (en) | Procedure for the treatment of severe heart failure and drug for this | |
SE9901573D0 (en) | New compounds | |
CA2379734A1 (en) | Treatment of cancers | |
EP1258250A4 (en) | Nerve protective drugs | |
SE9901572D0 (en) | New compounds | |
EA200300048A1 (en) | ENANTIOMER OF 1,2-ANNELIED HINAZOLINE INHIBITING PHARNESILTRANSFERASE | |
YU25202A (en) | Substituted pyrroles as antiproliferative agents for the treatment of cancer | |
MXPA02006146A (en) | Methods for treating psychological disorders using bioactive metabolites of gepirone. | |
AU4258601A (en) | Divided dose therapies with vascular damaging activity | |
SE9900190D0 (en) | New compounds | |
YU46302A (en) | Substituted pyrroles | |
AR063459A1 (en) | METHOD FOR MANAGING AN AURORA INHIBITOR IN CANCER TREATMENT | |
WO2001007029A3 (en) | Substituted guanidines and the use thereof | |
EP1797884A3 (en) | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system | |
MY126998A (en) | Substituted pyrroles. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 541496 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2393252 Country of ref document: CA Ref document number: 20650/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000983966 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWP | Wipo information: published in national office |
Ref document number: 2000983966 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |